Other Information
+Added: Departure of Directors or Certain Officers
+Added: On October 26, 2023, the Company announced that Pritesh Shah will resign as Chief Growth Officer, effective January 1, 2024, and will remain with the Company in a non-executive capacity
Securities Trading Plans of Executive Officers and Directors
1 unchanged sentence
Our Insider Trading Policy permits our executive officers and directors to enter into trading plans designed to comply with Rule 10b5-1.
−Removed: The following table describes contracts, instructions or written plans for the purchase or sale of our securities that are intended to satisfy the affirmative defense conditions of Rule 10b5–1(c) promulgated under the Securities Exchange Act of 1934, as amended (each a "Rule 10b5-1 Plan") adopted by our executive officers and directors during the three month period ending June 30, 2023:
−Removed: Name and Title Date of Adoption Duration of Rule 10b5-1 Plan Aggregate Number of Securities to be Purchased Pursuant to the Rule 10b5-1 Plan Aggregate Number of Securities to be Sold Pursuant to the Rule 10b5-1 Plan
−Removed: Uri Weinberg, Chief Innovation Officer June 9, 2023 1/2/2024-12/31/2024 37,474 92,859
−Removed: Kinyip Gabriel Leung, Director June 8, 2023 9/7/2023-8/31/2024 18,136 70,136
−Removed: During the three-month period ending June 30, 2023, none of our executive officers or directors terminated a Rule 10b5-1 trading plan or adopted or terminated a non-Rule 10b5-1 trading arrangement (as defined in Item 408(c) of Regulation S-K).
+Added: The following table describes contracts, instructions or written plans for the purchase or sale of our securities that are intended to satisfy the affirmative defense conditions of Rule 10b5–1(c) promulgated under the Securities Exchange Act of 1934, as amended (each a "Rule 10b5-1 Plan") adopted by our executive officers and directors during the three month period ending September 30, 2023:
+Added: Title Date of Adoption Duration of Rule 10b5-1 Plan Aggregate Number of Securities to be Purchased Pursuant to the Rule 10b5-1 Plan Aggregate Number of Securities to be Sold Pursuant to the Rule 10b5-1 Plan
+Added: Chief Growth Officer
+Added: August 8, 2023 8/30/2024 — 103,304
+Added: During the three-month period ending September 30, 2023, none of our executive officers or directors terminated a Rule 10b5-1 trading plan or adopted or terminated a non-Rule 10b5-1 trading arrangement (as defined in Item 408(c) of Regulation S-K).
EXHIBIT INDEX
16 unchanged sentences
NovoCure Limited
−Removed: July 27, 2023 /s/ Ashley Cordova
+Added: October 26, 2023 /s/ Ashley Cordova
Ashley Cordova
3 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.